Metrion provides a fully integrated cardiac safety screening service incorporating all three components of the Comprehensive In vitro Proarrhythmia (CiPA) initiative. Our services include:

  1. Automated electrophysiology screening against an expanded panel of six cardiac ion channels, including hERG.
  2. In silico modelling using electrophysiology data from the expanded ion channel panel.
  3. Confirmation of in silico predictions using translational assays employing human iPSC-derived cardiomyocytes.

Metrion is a member of the HESI Cardiac Safety committee and, as part of its role in the HTS sub team, is involved in validating automated screening assays. The company also has access to multiple commercially available iPSC-derived cardiomyocyte cell lines, which have been fully validated in-house.